Healthcare facility QuVa Pharma stated on Thursday the it will supply the Dexamethasone Phosphate as a compounded sterile product in ready-to-administer in 6mg in 25ml 0.9% sodium chloride IV bag for critically-ill Covid-19 patients under FDA Drug Shortage guidelines.
The company added that the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel and the World Health Organization (WHO) updated their recommendations to include systemic corticosteroids, including Dexamethasone 6mg daily, for hospitalized patients with severe and critical COVID-19.
Follow the results of the UK RECOVERY trial, the European Medicines Agency's drug evaluation committee, CHMP, has endorsed Dexamethasone use, 6mg once per day for up to ten days, for hospitalized COVID-19 patients who require oxygen, stated the company.
COVID-19 demonstrates how a uniquely positioned 503B services platform like QuVa can quickly respond to hospitals' pharmaceutical needs and support them in improving patient care, according to its co-founder and CDO Peter Jenkins.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML